A clinical trial of AO-176 in combination with pembrolizumab (KEYTRUDA®) in solid tumors
Latest Information Update: 05 May 2021
At a glance
- Drugs AO 176 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Arch Oncology
- 05 May 2021 New trial record